共 50 条
- [31] Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancerCANCER RESEARCH, 2013, 73Elias, A.Modi, S.Krop, I. E.Pegram, M.Ipe, D.Guardino, E. A.Althaus, B.LoRusso, P. L.
- [32] Pharmacokinetic (PK) Interaction Potential of Trastuzumab-DM1 (T-DM1) and Pertuzumab (P) in Pts with HER2-Positive, Locally Advanced or MBC: Results from a Phase 1b/2 StudyCANCER RESEARCH, 2010, 70Burris, H. A., IIILu, D.Dees, E. C.Cortes, J.Yi, J-HShih, T.Girish, S.
- [33] Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trialCANCER RESEARCH, 2009, 69 (02) : 70S - 71SGianni, L.Eiermann, W.Semiglazov, VManikhas, G. M.Lluch, A.Tjulandin, S.Feyereislova, A.Valagussa, P.Baselga, J.
- [34] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib StudyONCOLOGY, 2019, 96 (06) : 309 - 317Kojima, YasuyukiYoshie, ReikoKawamoto, HisanoriShimo, ArataUejima, TomokoIwatani, TsuguoMotoyoshi, AiKanemaki, YoshihideBoku, NarikazuTsugawa, Koichiro
- [35] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLANCET ONCOLOGY, 2012, 13 (01): : 25 - 32Gianni, LucaPienkowski, TadeuszIm, Young-HyuckRoman, LasloTseng, Ling-MingLiu, Mei-ChingLluch, AnaStaroslawska, Elzbietade la Haba-Rodriguez, JuanIm, Seock-AhPedrini, Jose LuizPoirier, BrigitteMorandi, PaoloSemiglazov, VladimirSrimuninnimit, VichienBianchi, GiuliaSzado, TaniaRatnayake, JayanthaRoss, GrahamValagussa, Pinuccia
- [36] MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Ellis, P. A.Barrios, C. H.Im, Y.Patre, M.Branle, F.Perez, E. A.
- [37] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast CancerPHARMACOECONOMICS, 2015, 33 (01) : 13 - 23Fleeman, NigelBagust, AdrianBeale, SophieDwan, KerryDickson, RumonaProudlove, ChrisDundar, Yenal
- [38] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast CancerPharmacoEconomics, 2015, 33 : 13 - 23Nigel FleemanAdrian BagustSophie BealeKerry DwanRumona DicksonChris ProudloveYenal Dundar
- [39] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 studyCANCER RESEARCH, 2018, 78 (13)Cortes, JavierDieras, VeroniqueLorenzen, SylvieMontemurro, FilippoRiera-Knorrenschild, JorgeThuss-Patience, PeterAllegrini, GiacomoDe laurentiis, MicheleLichinitser, MikhailLohrisch, CarolinePerez-Garcia, JoseRicci, FrancescoSakaeva, DinaSerpanchy, RosanneSufliarsky, JozefVidal, MariaIrahara, NatsumiWohlfarth, ChristineAout, MounirGelmon, Karen
- [40] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Cascetta, Krystal PaulinePoulikakos, PoulikosShapiro, Charles L.Bhardwaj, Aarti SoniaFasano, JulieIrie, HannaKlein, PaulaGoel, AnupamaKalinsky, KevinAdams, SylviaAndreopoulou, EleniJaffer, ShabnamRu, MengTiersten, Amy